Vaccination with a live RA 27/3 strain rubella vaccine (Rudivax), a follow-up study.
Thirteen-year-old Helsinki schoolgirls were screened for rubella antibodies using fingertip blood specimens and the single radial haemolysis (SRH) test. The seronegative individuals (326/1234; 26.4%) were immunized with the RA 27/3 strain of rubella vaccine (Rudivax). All 326 produced SRH and haemagglutinin inhibition (HAI) antibodies and 129 IgM antibodies (39.4%) detected by enzyme immunoassay in the two-month follow-up serum samples. The incidence and nature of side effects was low. In the twenty-four month follow-up serum samples all individuals had substantial levels of rubella antibodies and no clinical reinfections had occurred during the observation period.
D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis*; D005260:Female; D005500:Follow-Up Studies; D006385:Hemagglutination Inhibition Tests; D006461:Hemolysis; D006801:Humans; D012409:Rubella / Q000517:prevention & control*; D012411:Rubella Vaccine / Q000008:administration & dosage*; D012412:Rubella virus / Q000276:immunology*; D014611:Vaccination
D000914:Antibodies, Viral; D012411:Rubella Vaccine